이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Beijing Hotgen Biotech 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Changqing Lin

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	25.0%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2yrs

최근 관리 업데이트

Recent updates

There's Reason For Concern Over Beijing Hotgen Biotech Co., Ltd.'s (SHSE:688068) Massive 28% Price Jump

Mar 06

CEO

Changqing Lin (48 yo)

no data

테뉴어

CN¥6,129,000

보상

Mr. Changqing Lin serves as Chairman of the Board and General Manager at Beijing Hotgen Biotech Co., Ltd.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Changqing Lin	Chairman & GM	no data	CN¥6.13m	24.95% CN¥ 561.6m
Shen Qi	Director	no data	데이터 없음	데이터 없음
Jing Li	Chairman of the Supervisory Board	no data	데이터 없음	데이터 없음
Qi Gao	Supervisor	2.9yrs	데이터 없음	데이터 없음
Xiaoli Liu	Director	2yrs	CN¥1.94m	0.015% CN¥ 345.0k
Changyuan Yu	Independent Director	2yrs	CN¥60.00k	데이터 없음

2.0yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 이사회: 688068 의 이사회는 경험(평균 재직 기간 1.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Beijing Hotgen Biotech 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Recent updates

Beijing Hotgen Biotech Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024

New minor risk - Dividend sustainability

Beijing Hotgen Biotech Co., Ltd., Annual General Meeting, May 21, 2024

Full year 2023 earnings released: EPS: CN¥0.31 (vs CN¥10.33 in FY 2022)

Beijing Hotgen Biotech Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

There's Reason For Concern Over Beijing Hotgen Biotech Co., Ltd.'s (SHSE:688068) Massive 28% Price Jump

Full year 2023 earnings released: EPS: CN¥0.34 (vs CN¥10.33 in FY 2022)

Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 150 million worth of its shares.

Beijing Hotgen Biotech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥3.12 profit in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

New minor risk - Share price stability

Second quarter 2023 earnings released: EPS: CN¥0.29 (vs CN¥2.27 in 2Q 2022)

Beijing Hotgen Biotech Co., Ltd. to Report First Half, 2023 Results on Aug 30, 2023

Full year 2022 earnings released: EPS: CN¥12.13 (vs CN¥23.74 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥3.12 (vs CN¥0.26 in 3Q 2021)

Investor sentiment improved over the past week

Beijing Hotgen Biotech Co., Ltd. (SHSE:688068) announces an Equity Buyback for CNY 300 million worth of its shares.

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥13.69 (vs CN¥0.018 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥9.67 (vs CN¥0.01 in 1Q 2020)

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥1.79 (vs CN¥0.67 in FY 2019)

New 90-day low: CN¥34.59

New 90-day low: CN¥37.10

New 90-day low: CN¥41.40

Beijing Hotgen Biotech Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥46.23

New 90-day low - CN¥50.51

Beijing Hotgen Biotech Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령